Humacyte, Inc. — Form 8-K
Filed July 31, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
On July 31, 2026, Humacyte, Inc. filed an 8-K disclosing Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. The filing indicates the company has violated Nasdaq (or similar exchange) continued listing requirements. The specific rule(s) violated, timeline for remediation, and detailed circumstances are not disclosed in the excerpt provided.
Why this rating
Delisting is business-changing: loss of public market access, credibility damage, reduced liquidity, likely stock-price collapse. Existential threat to $280M public company.
Extracted items
See more from July 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.